The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.
As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are still very popular and remain effective methods of fighting the disease as a whole.
The automation of immunoassays is not a new trend, but one that has already witnessed decades of innovation. However, in terms of hands-free automated processing of small batches of immunoassays, the potential end-user is fortunate to be presented with an increasing number of choices.
Therapeutic drug monitoring services are a vital part of the pathology laboratoryâs remit, providing essential clinical information to guide the management and treatment of a wide range of patients, from those with psychiatric disorders to post-transplantation care.
The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market value of $60 billion.